{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CLPT",
  "name": "ClearPoint Neuro, Inc.",
  "url": "https://frontierpicks.com/dossiers/CLPT/",
  "json_url": "https://frontierpicks.com/dossiers/CLPT.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72 (7/02) but the theme has cooled to maturing, with no dated catalyst inside 30 days except the ~mid-August Q2 print. A base-watch, not a momentum entry.",
  "invalidation_trigger": "A weekly close below $16 loses the post-catalyst breakout shelf (6/18 gap close $16.81) and unwinds the June re-rate; secondary breaks: the AMT-130 Huntington's BLA slips the Q3-2026 window or draws an FDA refuse-to-file, or FY2026 revenue guide is cut below the $52M floor.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-14",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics",
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Trades as a uniQure delivery-sympathy proxy: AMT-130 regulatory and data headlines move the tape more than ClearPoint's own reported numbers.",
    "S-3 shelf on file; Oberland note facility carries $25M and $50M tranches drawable before 2026-12-31 — a standing financing overhang.",
    "FY2026 revenue guidance is $48-52M as of 2026-08-03, cut from $52-56M; any model built on the older range is stale.",
    "The $500M 'Essential. Everywhere.' revenue ambition ($200M four pillars + $300M commercial drug delivery) carries no company-stated target year.",
    "Q2 2026 opex included the IRRAS acquisition and the CAL Torrey Pines facility taken over in July 2026; the cost base is not comparable to prior-year quarters.",
    "The September AMT-130 four-year readout has no announced date or venue as of 2026-08-23; uniQure has guided only to the month."
  ],
  "body_markdown": "## Current Thesis\nThe leg on offer is per-procedure delivery economics on CNS gene therapy: ClearPoint's SmartFlow cannula plus MRI/iCT navigation is the route partner programs use to put a molecule into the brain, so the company bills on the build-out whichever therapy clears first. Three weeks past the 2026-08-03 print, that frame is intact while the price expression of it has broken. Q2 revenue was $10.88M against $12.73M consensus, EPS -$0.38 against -$0.29, FY2026 guidance was cut to $48–52M from $52–56M, and the segment that carries the thesis — biologics and drug delivery — fell 15% YoY to $4M on lower biopharma trial initiations. The $16 shelf that framed the June re-rate went with it. Two consecutive weekly closes now sit in the low $15s: $15.34 on 2026-08-14 and $15.39 on 2026-08-21, five cents apart, with RSI(14) drifting from 55.4 to 50.1. The stock is 48.0% under the $29.60 52-week high and still up 34.5% over three months. The narrative is maturing. New attention peaked in June (B. Riley maintained Buy and raised its target to $30 on 2026-06-18; the name ran in Benzinga's health-care movers lists on 2026-06-17 alongside uniQure), the sell-side band was marked down on 2026-08-04, and the trailing 30-day headline feed is empty. What resolves next belongs to uniQure, not to ClearPoint's own P&L: an undated September four-year AMT-130 topline and a Q3-2026 filing window that ends 2026-09-30.\n\n## Bull Case\n- uniQure's 2026-07-29 Q2 update states that official FDA meeting minutes received in July 2026 confirmed alignment that an accelerated-approval BLA for AMT-130 on existing clinical data is reasonable, with submission expected in Q3-2026. AMT-130 is administered through ClearPoint navigation and SmartFlow, so a first approved CNS gene therapy opens a per-procedure delivery line.\n- A second regulator is on a parallel Q3 track: uniQure disclosed on 2026-04-30 that it held a UK MHRA pre-submission meeting covering the data package and manufacturing requirements, and plans an MAA submission in Q3-2026, leaning on three-year Phase I/II data showing 75% slowing of disease progression at the high dose versus external control (p=0.003).\n- September 2026 brings the largest single dataset yet on a ClearPoint-delivered program: four-year topline safety and efficacy on 24 patients (12 high-dose, 12 low-dose), cut as of 2026-06-30 per uniQure's 2026-07-29 release.\n- Q2 total revenue of $10.9M was still +18% YoY, carried by neurosurgery navigation, therapy products and capital equipment. The shortfall was concentrated in one segment.\n- ClearPoint Advanced Laboratories took full possession of the CAL Torrey Pines facility in July 2026; the August 2026 investor deck frames it as capable of more than $60M in annual revenue at full capacity versus roughly $8M at the prior subleased site, with minimal 2026 revenue recognized. A first GLP IND-enabling preclinical study is signed for 2027 completion.\n- Both sell-side targets cut on 2026-08-04 still sit above the tape: Lake Street $25 (from $30) and Stifel $22 (from $25), against the 2026-08-21 close of $15.39.\n\n## Bear Case\n- The structural damage is already on the chart. The 6/18 gap close of $16.81 and the $16 shelf that held through July are now overhead; two weekly closes since the print have failed to reclaim either.\n- FY2026 revenue guidance of $48–52M, cut from $52–56M on 2026-08-03, means the delivery segment is contracting in the year the equity is priced for its expansion. Biologics and drug delivery at $4M, -15% YoY, is the line meant to compound.\n- Cost is outrunning revenue: Q2 operating expenses +51% to $17.0M on the IRRAS acquisition and team expansion, gross margin 62% versus 64% in Q1.\n- Cash and equivalents fell to $29.4M at 2026-06-30 from $45.9M at 2025-12-31, roughly $16.5M consumed in H1 2026. An S-3 shelf is on file and the Oberland note facility carries $25M and $50M tranches drawable before 2026-12-31 — a standing financing decision that lands inside the next two quarters.\n- Direction is set by a company ClearPoint does not control. The September AMT-130 readout is a binary on someone else's asset, and the sympathy works in both directions.\n- No ClearPoint-dated event sits inside the next 30 days, so the guide cut has no company-level rebuttal until the Q3 print in roughly November.\n\n## Setup & Price Structure\n- Measured: the 2026-08-21 close of $15.39, 48.0% below the $29.60 52-week high, up 34.5% over three months, RSI(14) at 50.1 versus 55.4 a week earlier.\n- The two most recent weekly closes are $15.34 (2026-08-14) and $15.39 (2026-08-21) — a five-cent week with momentum bleeding to the midline. That is compression under resistance, not a reclaim of it.\n- Reference levels: $16.81 is the 2026-06-18 gap close and the top of the failed shelf; the $16 area is the line the June re-rate was built on and has not been recovered since 2026-08-03; the roughly $13 print in the after-hours reaction to the Q2 release is the last identifiable demand area beneath the current range.\n- Crowding evidence points thin rather than crowded: the coverage feed carries no headline in the trailing 30 days, the last flow-generating items being 2026-06-17 and 2026-06-18. Two price targets were reduced on 2026-08-04. There is no imminent company earnings date to force positioning.\n- The issuance channel is open and observable: $29.4M cash, an S-3 on file, and the 2026-12-31 Oberland deadline. Any offering, ATM usage, or tranche draw would be disclosed and is the cleanest read on whether the balance sheet gets fixed from strength or from necessity.\n\n## Catalyst Calendar (next 30 days)\n\n- ~2026-09-30 (est.): close of the Q3-2026 window uniQure has guided for the US BLA submission for AMT-130.\n- ~2026-09-30 (est.): close of the Q3-2026 window uniQure guided on 2026-04-30 for the UK MHRA MAA submission.\n- Outside the window but dated for context: ClearPoint Q3 2026 results ~2026-11 (est.), the first test of the $48–52M guide; and 2026-12-31, the deadline to draw the $25M and $50M Oberland tranches.\n\n## Elapsed catalysts\n\n- ~2026-09 (est., no date announced): uniQure presents four-year AMT-130 Phase I/II topline on 24 patients, data cut 2026-06-30. The durability read the 2027 launch assumption rests on. *(passed 57d ago)*\n\n## What Would Change Our Mind\nThe June structure is already gone — that break happened on 2026-08-03 and has not been repaired in the eleven trading days since. What remains is the post-print range, and a weekly close below $13 would surrender it entirely, putting the tape back at the reaction area from the guidance-cut session and leaving no dated ClearPoint event to arrest it before the November print. Two non-price conditions carry equal weight. First, the September window elapsing without the four-year AMT-130 topline, or a topline showing cUHDRS separation below the 75% slowing cited at three years, removes the durability leg the 2027 delivery revenue assumption depends on. Second, 2026-09-30 passing with neither the US BLA nor the UK MAA submitted would mean the confirmatory-study design is still unresolved and the approval clock has not started. On the other side, a weekly close back above $16.81 would restore the June shelf as support and reopen the re-rate that the guidance cut interrupted; a Q3 print showing biologics and drug delivery revenue growing again YoY would remove the fundamental objection rather than the technical one. The theme label moves from maturing to saturated if the September data lands and the stock does not extend on it.\n\n## Correlation Notes\n- The dominant correlation is to uniQure (QURE). On 2026-06-17 both names appeared in the same intraday movers list, and every dated catalyst inside the next 30 days is a uniQure event. Regulatory or data headlines on AMT-130 move CLPT more than ClearPoint's own reported revenue did on 2026-08-03.\n- Secondary exposure is the CNS gene-therapy and rare-disease complex generally: management flagged on the Q2 release \"renewed FDA openness to rare disease BLAs that could lead to commercial cell and gene therapy approvals starting in 2027,\" which ties the multiple to agency stance rather than to unit volumes.\n- As a cash-consuming small-cap medtech with $29.4M on hand at 2026-06-30 and an open shelf, the name also carries the funding-window sensitivity of the wider unprofitable small-cap complex — risk appetite and issuance conditions feed straight into the financing decision due before 2026-12-31.",
  "first_seen": "2026-06-17",
  "last_analyzed": "2026-08-23T12:36:52+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}